InvestorsHub Logo
Followers 118
Posts 19106
Boards Moderated 0
Alias Born 08/27/2005

Re: sharpei post# 293160

Wednesday, 07/04/2018 3:27:20 AM

Wednesday, July 04, 2018 3:27:20 AM

Post# of 402518
Thanks sharpie. A very happy fourth to you as well.
Keep those chart interpretations coming once this gets rolling. Elite not rolling yet, but volume shows renewed interest now that they got their first ANDA approved.

Any number of things can happen, including the undisclosed ANDA. Another, isradipine, could be as WeeZuhl posted, a dark horse. Since only Teva and Elite manufacture this generic it could bode very well for Elite.

With over 1 million in the US alone that have Parkinson's and only two current pharmas producing it, this could turn out to be a very nice money maker for Elite.
Thanks for that information Gman.

An excerpt from a June 29, 2016 Foxfeed article about isradipine.

"Isradipine is a calcium channel blocker currently prescribed to treat high blood pressure. It came to the attention of Parkinson’s researchers when data from large studies showed lower risk of Parkinson’s disease (PD) among people who took the drug for hypertension. Scientists believe isradipine works to prevent the death of dopamine-producing cells and therefore may slow the progression of PD. The Michael J. Fox Foundation (MJFF) funded pre-clinical work to make that connection, as well as the Phase II trial. In 2014, isradipine researchers received a $23 million grant from the National Institutes of Health to move the Safety, Tolerability and Efficacy Assessment of Dynacirc® for PD (STEADY-PD) study into Phase III efficacy testing. Dynacirc® is the commercial name of the isradipine hypertension drug."
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ELTP News